Kerry Breen is a news editor at CBSNews.com. A graduate of New York University's Arthur L. Carter School of Journalism, she previously worked at NBC News' TODAY Digital. She covers current events, ...

The journal Pituitary has highlighted research led by Manel Puig, head of the Endocrine, Thyroid and Obesity Research Group ...

Imagine living with unexplained changes and health issues for nearly a decade, only to discover it's a rare disease that was, until recently, very difficult to treat and can affect nearly every aspect ...

Learn about Acromegaly disease, its symptoms like enlarged hands and facial features, and explore effective Acromegaly ...

A personalized treatment protocol was more effective for management of acromegaly -- also known as gigantism -- than the usual trial-and-error approach, the ...

SAN DIEGO — Crinetics Pharmaceuticals announced on Sunday that its experimental drug for acromegaly, a rare and serious hormonal disorder, succeeded in a late-stage trial, bringing the San Diego ...

Las Vegas woman has uncontrolled growth that may slow with heavy doses of meds. May 24, 2011— -- At 6-foot 11-inches tall and 344 pounds, Tanya Angus, who has a rare disease that causes gigantism ...

An investigational treatment for acromegaly -- also known as gigantism -- was safe and boosted biochemical control, according to final topline findings of the phase III ACROINNOVA 2 study. Meeting the ...

Please provide your email address to receive an email when new articles are posted on . Most adults with acromegaly maintained or improved IGF-I levels with oral octreotide in three phase 3 trials.

Crinetics Pharmaceuticals (CRNX) just received FDA approval for PALSONIFY, a once-daily oral treatment for adults with acromegaly who have not responded to surgery, or for those for whom surgery is ...

(RTTNews) - Crinetics Pharmaceuticals Inc. (CRNX) said that paltusotine, an oral, once-daily investigational compound, achieved positive results by meeting the primary endpoint and all secondary ...